Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047385 · ClinicalTrials.gov registry record · Phase 3
National Lung Screening Trial (NLST) Screening
A Phase 3 study of Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 53,454
- Enrollment target
- 20
- Study locations
NCT00047385: Completed Phase 3 study of Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00047385 is a Phase 3 study of Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53,454 participants, above the 805-participant average among 409 other Lung Cancer trials with a reported enrollment target (6540% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047385, a Phase 3 study of Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 53,454 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Effective screening tests should help doctors detect lung cancer early and plan curative treatment. It is not yet known whether low-dose helical computed tomography (LDCT) screening is more effective than chest radiography (CXR) screening in reducing death from lung cancer. PURPOSE: Randomized clinical trial to compare the effectiveness of LDCT scan with that of CXR in screening individuals who are at high risk for developing lung cancer.
Primary Outcome
Lung cancer deaths confirmed in participants by Endpoint Verification if available, otherwise by death certificate.
Conditions Studied
Interventions
- DEVICE low-dose helical computed tomography
- DEVICE chest radiography
Study Locations (20)
California
- Univeristy of California, San Diego - La Jolla
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Florida
- Mayo Clinic - Jacksonville
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Massachusetts
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Henry Ford Health System - Detroit
Minnesota
- University of Minnesota School of Public Health - Minneapolis
- Mayo Clinic Cancer Center - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado Denver - Denver
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53,454 participants |
| Start Date | 2002-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
What the finished NCT00047385 record still lists
NCT00047385 is an interventional study that assigns participants to a tested intervention. Its 53,454 participants enrollment target places it among the larger protocols in the corpus, above the 805-participant average among 409 other Lung Cancer trials with a reported enrollment target (6540% higher).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which low-dose helical computed tomography is the first listed.
NCT00047385 names 20 study sites across 15 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00047385 about?
NCT00047385 is a clinical study titled "National Lung Screening Trial (NLST) Screening". RATIONALE: Effective screening tests should help doctors detect lung cancer early and plan curative treatment. It is not yet known whether low-dose helical computed tomography (LDCT) screening is more effective than chest radiography (CXR) screening in reducing death from lung cancer. PURPOSE: Rand...
What is the current status of trial NCT00047385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 53,454 participants. The study started on 2002-08. Estimated completion is 2010-10.
What conditions does trial NCT00047385 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00047385?
The interventions under investigation include: low-dose helical computed tomography (DEVICE), chest radiography (DEVICE).
Who is sponsoring clinical trial NCT00047385?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047385 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00047385's enrollment target sits among peer trials
53,454 1st of 409 higher than 409 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia